Activity Overview
This online, on-demand virtual symposium brings together renowned experts in hematologic malignancies. In this educational program, these experts discuss the current and emerging use of CAR T-cell therapies in the clinic, particularly where these techniques fit into the standard of care. After an overview of data supporting the current options, case discussions focus on decision-making for patients with B-cell malignancies or multiple myeloma, with an emphasis on identifying appropriate candidates for this approach.
This educational activity is an archive of the live symposium held on June 19, 2026.
Target Audience
This educational activity is directed toward medical oncologists, hematologist-oncologists, hematologists, advanced practice providers, nurses, and other health care professionals involved in the management of hematologic malignancies.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply the latest evidence to identify appropriate patients with hematologic malignancies for CAR T-cell therapy
- Evaluate the efficacy and safety data across FDA-approved CAR T-cell therapies for hematologic malignancies to inform clinical decision-making
Jesús G. Berdeja, MD
Director, Multiple Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, TN
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Bristol Myers Squibb, Galapagos, Janssen, Johnson & Johnson, Karyopharm, Kite Pharma, Kyowa Kirin, Pfizer, Regeneron, Roche, Whitehawk Therapeutics; Grant/Research Funding: AstraZeneca, Bristol Myers Squibb, C4 Therapeutics, Caribou Biosciences, GSK, Genentech, Gracell Biotechnologies, Ichnos Sciences, Johnson & Johnson, Juno Therapeutics, K36 Therapeutics, Karyopharm, Kite Pharma, Pfizer, Roche, Sanofi
Michael Byrne, DO, FACP
Director of Cellular Therapy Research
Greco-Hainsworth Centers for Research
Director, Cellular Therapy Program
Tennessee Oncology
Medical Director for Cellular Therapy
OneOncology
Nashville, TN
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Concert Pharmaceuticals (DSMC)
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.